# A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor

> **NCT01851070** · PHASE2 · COMPLETED · sponsor: **Mesoblast, Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Allogeneic Mesenchymal Precursor Cells
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT01851070
- **Lead sponsor:** Mesoblast, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2016-05
- **Final completion:** 2017-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01851070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01851070, "A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01851070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*